RECRUITINGOBSERVATIONAL
Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients
About This Trial
PROQEM is a prospective cohort study among patients diagnosed with uveal melanoma to assess quality of life before and in the first five years after treatment.
Who May Be Eligible (Plain English)
Who May Qualify:
- Age ≥18 years
- Clinical or pathological diagnosis of a melanoma of the choroid or ciliary body
- No signs of metastasis after staging procedures with at least an X-thorax, blood test and an ultrasound of the liver
- Treatment by brachytherapy, proton therapy or enucleation
Who Should NOT Join This Trial:
- None
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Age ≥18 years
* Clinical or pathological diagnosis of a melanoma of the choroid or ciliary body
* No signs of metastasis after staging procedures with at least an X-thorax, blood test and an ultrasound of the liver
* Treatment by brachytherapy, proton therapy or enucleation
Exclusion Criteria:
* None
Treatments Being Tested
OTHER
Quality of life questionnaires
Collection of patient-reported outcomes concerning general and health-related quality of life and impact of uveal melanoma diagnosis
OTHER
Discrete choice experiment
Assessment of patient preferences for outcomes of proton therapy and enucleation
OTHER
Shared decision-making analysis
Assessment of shared decision-making from the perspective of the patient (by questionnaire), physician (by questionnaire) and a neutral observer (by audiotape), combined with patient-reported satisfaction and regret of the treatment decision (by questionnaire)
OTHER
Impact of side-effects analysis
Assessment of the impact of side-effects by questionnaire
Locations (1)
Leiden University Medical Center
Leiden, South Holland, Netherlands